The DOI matches its Crossref record.
Targeting the EGFR Pathway for Cancer Therapy
Open accessAbstract
Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant to conventional chemo-therapies. Additionally, in most patients with multiple myeloma, the malignant cells over-express a number of epidermal growth factor receptors (EGFR)s and their ligands, HB-EGF and amphiregulin, thus this growth-factor family may be an important aspect in the patho-biology of this disease. These and other, related findings have provided the rationale for the targeting of the components of the EGFR signaling pathways for cancer therapy. Below we discuss various aspects of EGFR-targeted therapies mainly in hematologic malignancies, lung cancer and breast cancer. Beside novel therapeutic approaches, we also discuss specific side effects associated with the therapeutic inhibition of components of the EGFR-pathways. Alongside small inhibitors, such as Lapatinib (Tykerb, GW572016), Gefitinib (Iressa, ZD1839), and Erlotinib (Tarceva, OSI-774), a significant part of the review is also dedicated to therapeutic antibodies (e.g.: Trastuzumab/Herceptin, Pertuzumab/Omnitarg/rhuMab-2C4, Cetuximab/Erbitux/IMC-C225, Panitumumab/Abenix/ABX-EGF, and also ZD6474). In addition, we summarize, both current therapy development driven by antibody-based targeting of the EGFR-dependent signaling pathways, and furthermore, we provide a background on the history and the development of therapeutic antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Progress in the treatment of advanced gastric cancer
Song, Z., Wu, Y., Yang, J., Yang, D., & Fang, X. (2017) · Tumor Biology · doi:10.1177/1010428317714626 · Cited by 924
MADDIKA, S., ANDE, S., PANIGRAHI, S., PARANJOTHY, T., WEGLARCZYK, K., ZUSE, A., ESHRAGHI, M., MANDA, K., WIECHEC, E., & LOS, M. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.01.003 · Cited by 461
Self-citationCancer stem cell markers in common cancers – therapeutic implications
Klonisch, T., Wiechec, E., Hombach-Klonisch, S., Ande, S. R., Wesselborg, S., Schulze-Osthoff, K., & Los, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.08.003 · Cited by 393
Self-citationReceptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279
Metadata
- Authors
- Johnston, J., Navaratnam, S., Pitz, M., Maniate, J., Wiechec, E., Baust, H., Gingerich, J., Skliris, G., Murphy, L., & Los, M.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-12-01
- Volume
- 13
- Issue
- 29
- Pages
- 3483-3492
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2168391786
- Cited by
- 183
- References
- 0
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the EGFR Pathway for Cancer Therapy. https://app.cochat.ai/papers/10.2174/092986706779026174
- The paper
- Johnston, J., Navaratnam, S., Pitz, M., Maniate, J., Wiechec, E., Baust, H., Gingerich, J., Skliris, G., Murphy, L., & Los, M. (2006). Targeting the EGFR Pathway for Cancer Therapy. Current Medicinal Chemistry. https://doi.org/10.2174/092986706779026174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.